114 related articles for article (PubMed ID: 7197965)
1. Pharmacokinetics of oxazepam following multiple administration in volunteers and patients with chronic renal disease.
Busch U; Molzahn M; Bozler G; Koss FW
Arzneimittelforschung; 1981; 31(9):1507-11. PubMed ID: 7197965
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
4. Oxazepam disposition in uremic patients.
Odar-Cederlöf I; Vessman J; Alván G; Sjöqvist F
Acta Pharmacol Toxicol (Copenh); 1977 Jan; 40 Suppl 1(1):52-62. PubMed ID: 300542
[TBL] [Abstract][Full Text] [Related]
5. Oxazepam kinetics: effects of age and sex.
Greenblatt DJ; Divoll M; Harmatz JS; Shader RI
J Pharmacol Exp Ther; 1980 Oct; 215(1):86-91. PubMed ID: 7452494
[TBL] [Abstract][Full Text] [Related]
6. The protein binding of diazepam and N-demethyldiazepam in patients with poor renal function.
Kangas L; Kanto J; Forsström J; Iisalo E
Clin Nephrol; 1976 Mar; 5(3):114-8. PubMed ID: 1261102
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of oxazepam in healthy volunteers.
Alván G; Siwers B; Vessman J
Acta Pharmacol Toxicol (Copenh); 1977 Jan; 40 Suppl 1(1):40-51. PubMed ID: 300541
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
[TBL] [Abstract][Full Text] [Related]
9. [Clearance concept applied to pharmacokinetics: 2. Experience with tolamolol (beta-blocking agent) in renal insufficiency (author's transl)].
Balant L; Gorgia A; Marmy A; Tschopp JM
Nephrologie; 1980; 1(4):177-82. PubMed ID: 6895408
[TBL] [Abstract][Full Text] [Related]
10. Lorcainide kinetics and protein binding in patients with end-stage renal disease.
Somani P; Simon V; Gupta RK; King P; Shapiro RS; Stockard H
Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):121-5. PubMed ID: 6715079
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of iopamidol in adults with renal failure.
Corradi A; Menta R; Cambi V; Maccarini P; Cerutti R
Arzneimittelforschung; 1990 Jul; 40(7):830-2. PubMed ID: 2222559
[TBL] [Abstract][Full Text] [Related]
12. The influence of diflunisal on the pharmacokinetics of oxazepam.
van Hecken AM; Tjandramaga TB; Verbesselt R; de Schepper PJ
Br J Clin Pharmacol; 1985 Sep; 20(3):225-34. PubMed ID: 4041343
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacokinetics of oral prazepam].
Kölle EU
Fortschr Med; 1981 Jun; 99(22):874-9. PubMed ID: 6790396
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of piroxicam.
Verbeeck RK; Richardson CJ; Blocka KL
J Rheumatol; 1986 Aug; 13(4):789-96. PubMed ID: 3490574
[TBL] [Abstract][Full Text] [Related]
15. Plasma protein binding of drugs and adjustment of their dosing regimen in patients with chronic renal failure.
Schück O
Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):476-8. PubMed ID: 3679618
[TBL] [Abstract][Full Text] [Related]
16. Steady-state pharmacokinetics of ipriflavone and its metabolites in patients with renal failure.
Rondelli I; Acerbi D; Ventura P
Int J Clin Pharmacol Res; 1991; 11(4):183-92. PubMed ID: 1813437
[TBL] [Abstract][Full Text] [Related]
17. Multiple oral doses of diazepam, oxazepam and phenobarbital to dogs--behavioural effects and correlation with antipyrine half-life.
Albanus L; Jönsson M; Sparf B
Acta Pharmacol Toxicol (Copenh); 1977 Jan; 40 Suppl 1(1):63-9. PubMed ID: 300543
[TBL] [Abstract][Full Text] [Related]
18. Disposition of remoxipride in different species. Species differences in metabolism.
Widman M; Nilsson LB; Bryske B; Lundström J
Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
[TBL] [Abstract][Full Text] [Related]
19. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
Haffner D; Schaefer F; Girard J; Ritz E; Mehls O
J Clin Invest; 1994 Mar; 93(3):1163-71. PubMed ID: 8132756
[TBL] [Abstract][Full Text] [Related]
20. [Elimination half-life and serum protein binding of the anti-rheumatism agent naproxen in kidney failure].
Held H
Z Rheumatol; 1979; 38(3-4):111-9. PubMed ID: 442840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
